IFOSFAMIDE-INDUCED NEUROTOXICITY

被引:42
作者
CURTIN, JP
KOONINGS, PP
GUTIERREZ, M
SCHLAERTH, JB
MORROW, CP
机构
关键词
D O I
10.1016/0090-8258(91)90344-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ifosfamide is an active chemotherapeutic agent in a wide range of gynecologic tumors; favorable response rates have been reported in ovarian (epithelial and germ cell), uterine, and cervical neoplasms. Central neurotoxicity is a known, but poorly described side effect. We report 23 patients who received a total of 75 cycles of ifosfamide, either as a single agent or in combination with other chemotherapeutic agents. Six of twenty-three (26%) experienced grade 4 neurotoxicity; clinical presentation included confusion, aphasia, hallucinations, and coma. All patients exhibited the first evidence of neurotoxicity by the end of the 24-hr infusion. Three of six patients with grade 4 neurotoxicity expired within 14 days of receiving ifosfamide. The neurotoxicity resolved over 2 to 4 days in the remaining patients. Serum albumin was normal (> 3.5 g/dl) in 63 cycles of ifosfamide not associated with neurotoxicity. When serum albumin was <3.5 g/dl, 6 of 12 cycles were associated with severe neurotoxicity (P < 0.001). Low serum albumin (< 3.5 g/dl) appears to be associated with a high risk of severe neurotoxicity in patients receiving single-dose ifosfamide therapy. © 1991.
引用
收藏
页码:193 / 196
页数:4
相关论文
共 9 条
[1]   IFOSFAMIDE ENCEPHALOPATHY [J].
DANESH, MM ;
DEGIORGIO, CM ;
BEYDOUN, SR ;
KEMPF, RA .
JOURNAL OF TOXICOLOGY-CLINICAL TOXICOLOGY, 1989, 27 (4-5) :293-298
[2]   HIGH-DOSE IFOSFAMIDE WITH MESNA UROPROTECTION - A PHASE-I STUDY [J].
ELIAS, AD ;
EDER, JP ;
SHEA, T ;
BEGG, CB ;
FREI, E ;
ANTMAN, KH .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (01) :170-178
[3]   PREDICTION OF IFOSFAMIDE MESNA ASSOCIATED ENCEPHALOPATHY [J].
MEANWELL, CA ;
BLAKE, AE ;
KELLY, KA ;
HONIGSBERGER, L ;
BLACKLEDGE, G .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1986, 22 (07) :815-819
[4]  
MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO
[5]  
2-6
[6]   CENTRAL-NERVOUS-SYSTEM TOXICITY FOLLOWING THE TREATMENT OF PEDIATRIC-PATIENTS WITH IFOSFAMIDE MESNA [J].
PRATT, CB ;
GREEN, AA ;
HOROWITZ, ME ;
MEYER, WH ;
ETCUBANAS, E ;
DOUGLASS, E ;
HAYES, FA ;
THOMPSON, E ;
WILIMAS, J ;
IGARASHI, M ;
KOVNAR, E .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (08) :1253-1261
[7]   PHASE-II TRIAL OF IFOSFAMIDE AND MESNA IN ADVANCED OVARIAN-CARCINOMA - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY [J].
SUTTON, GP ;
BLESSING, JA ;
HOMESLEY, HD ;
BERMAN, ML ;
MALFETANO, J .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) :1672-1676
[8]  
SUTTON GP, 1990, SEMIN ONCOL S, V4, P6
[9]   IFOSFAMIDE [J].
ZALUPSKI, M ;
BAKER, LH .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1988, 80 (08) :556-566